The growth of the global opioids market is driven by alarming an increase in incidence of orthopedic diseases & chronic pain. Furthermore, rise in disposable income and a surge in global geriatric population are expected to propel the growth of the global opioids market. However, emergence and legalization of cannabis as an alternative to opioids impede the growth of the market. On the contrary, an increase in consumption of opioid analgesic for pain management in developing countries is anticipated to create lucrative opportunities for market expansion in the near future.
The global opioid market is segmented into product, application, and region. Depending on product, the market is categorized into codeine, fentanyl, methadone, oxycodone, morphine, and hydrocodone. The applications covered in the market include pain management, cough treatment, and diarrhea treatment. The pain management segment is further classified into neuropathic pain, migraine, back pain, osteoarthritis pain, cancer pain, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
By Product Type
- Pain Management
- Cough Treatment
- Diarrhea Treatment
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Purdue Pharma
- Boehringer Ingelheim
- Janssen Pharmaceuticals, Inc.
- Sun Pharmaceuticals
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals Inc.
- Allergan, Plc
- Pfizer, Inc.
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Research Methodology
1.3.1. Secondary Research
1.3.2. Primary Research
1.3.3. Analyst Tools & Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Porter'S Five Forces Analysis
3.3. Top Player Positioning
3.4. Market Dynamics
18.104.22.168. Increase Use of Opioids In Pain Management
22.214.171.124. Upsurge In Consumption of Opioids In Developing Economies
126.96.36.199. Implementation of Stringent Government Regulation Toward Vigorous Prescription
188.8.131.52. Opioid Crisis Across The Globe
3.4.3. Impacting Factors
Chapter 4: Opioids Market, By Product
4.1.1. Market Size And Forecast, By Product Type
4.2.1. Key Market Trends
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3.1. Key Market Trends
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4.1. Key Market Trends
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country
4.5.1. Key Market Trends
4.5.2. Market Size And Forecast
4.5.3. Market Analysis, By Country
4.6.1. Key Market Trends
4.6.2. Market Size And Forecast
4.6.3. Market Analysis, By Country
4.7.1. Key Market Trends
4.7.2. Market Size And Forecast
4.7.3. Market Analysis, By Country
4.8.1. Key Market Trends
4.8.2. Market Size And Forecast
4.8.3. Market Analysis, By Country
Chapter 5: Opioids Market, By Application
5.1.1. Market Size And Forecast, By Application
5.2. Pain Management
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
184.108.40.206. Neuropathic Pain
220.127.116.11.1. Market Size And Forecast
18.104.22.168.1. Market Size And Forecast
22.214.171.124. Back Pain
126.96.36.199.1. Market Size And Forecast
188.8.131.52. Osteoarthritis Pain
184.108.40.206.1. Market Size And Forecast
220.127.116.11. Cancer Pain
18.104.22.168.1. Market Size And Forecast
22.214.171.124.1. Market Size And Forecast
5.3. Cough Treatment
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
5.4. Diarrhea Treatment
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country
Chapter 6: Opioids Market, By Region
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Market Trends
6.2.2. Market Size And Forecast, By Product
6.2.3. Market Size And Forecast, By Application
6.2.4. Market Size And Forecast, By Country
126.96.36.199. U.S. Market Size And Forecast, By Product
188.8.131.52. U.S. Market Size And Forecast, By Application
184.108.40.206. Canada Market Size And Forecast, By Product
220.127.116.11. Canada Market Size And Forecast, By Application
18.104.22.168. Mexico Market Size And Forecast, By Product
22.214.171.124. Mexico Market Size And Forecast, By Application
6.3.1. Key Market Trends
6.3.2. Market Size And Forecast, By Product
6.3.3. Market Size And Forecast, By Application
6.3.4. Market Size And Forecast, By Country
126.96.36.199. France Market Size And Forecast, By Product
188.8.131.52. France Market Size And Forecast, By Application
184.108.40.206. UK Market Size And Forecast, By Product
220.127.116.11. UK Market Size And Forecast, By Application
18.104.22.168. Germany Market Size And Forecast, By Product
22.214.171.124. Germany Market Size And Forecast, By Application
126.96.36.199. Spain Market Size And Forecast, By Product
188.8.131.52. Spain Market Size And Forecast, By Application
184.108.40.206. Rest of Europe Market Size And Forecast, By Product
220.127.116.11. Rest of Europe Market Size And Forecast, By Application
6.4.1. Key Market Trends
6.4.2. Market Size And Forecast, By Product
6.4.3. Market Size And Forecast, By Application
6.4.4. Market Size And Forecast, By Country
18.104.22.168. Japan Market Size And Forecast, By Product
22.214.171.124. Japan Market Size And Forecast, By Application
126.96.36.199. China Market Size And Forecast, By Product
188.8.131.52. China Market Size And Forecast, By Application
184.108.40.206. India Market Size And Forecast, By Product
220.127.116.11. India Market Size And Forecast, By Application
18.104.22.168. Australia Market Size And Forecast, By Product
22.214.171.124. Australia Market Size And Forecast, By Application
126.96.36.199. Taiwan Market Size And Forecast, By Product
188.8.131.52. Taiwan Market Size And Forecast, By Application
184.108.40.206. South Korea Market Size And Forecast, By Product
220.127.116.11. South Korea Market Size And Forecast, By Application
18.104.22.168. Rest of Asia-Pacific Market Size And Forecast, By Product
22.214.171.124. Rest of Asia-Pacific Market Size And Forecast, By Application
6.5.1. Key Market Trends
6.5.2. Market Size And Forecast, By Product
6.5.3. Market Size And Forecast, By Application
6.5.4. Market Size And Forecast, By Country
126.96.36.199. Brazil Market Size And Forecast, By Product
188.8.131.52. Brazil Market Size And Forecast, By Application
184.108.40.206. Turkey Market Size And Forecast, By Product
220.127.116.11. Turkey Market Size And Forecast, By Application
18.104.22.168. Saudi Arabia Market Size And Forecast, By Product
22.214.171.124. Saudi Arabia Market Size And Forecast, By Application
126.96.36.199. South Africa Market Size And Forecast, By Product
188.8.131.52. South Africa Market Size And Forecast, By Application
184.108.40.206. Rest of LAMEA Market Size And Forecast, By Product
220.127.116.11. Rest of LAMEA Market Size And Forecast, By Application
Chapter 7: Compony Profiles
7.1. Allergan Plc.
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Boehringer Ingelheim Group
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Endo Pharmaceuticals Inc. (Par Pharmaceutical)
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.4. Johnson & Johnson (Janssen Global Services, Llc)
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.5. Mallinckrodt Plc (Specgx Llc)
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.6. Pfizer Inc.
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Purdue Pharma L.P.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Sanofi S.A.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Sun Pharmaceutical Industries Ltd.
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.10. Teva Pharmaceutical Industries Limited
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
*Full List of Tables and Figures Available on Enquiry.
Opioid drugs are available legally by prescription, such as oxycodone (OxyContin), hydrocodone (Vicodin), codeine, morphine, and others. However, opioids comprise the illicit drug heroin, synthetic opioids including fentanyl, morphine, and other pain relievers.
The opioid market growth is majorly driven by surge in consumption of these drugs to combat pain and rise in geriatric population that are more prone to orthopedic pain. In addition, upsurge in disposable income in developing economies such as India, China, and others contribute to the growth of the market. However, surge in opioid addiction (opioid crisis) across the globe and implementation of stringent government regulation for opioid prescription are the factors anticipated to hamper the market growth. In addition, increase in death rates owing to the overdose of these drugs is a major factor restraining the market growth. For instance, according to the National Institute of Drug Abuse, more than 130 people in the U.S. die daily on overdosing of opioids.
Based on opioid market analysis, the oxycodone segment accounted for 23% of the share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to its increased intake across the globe for pain management. By application, the pain management segment dominated the opioid market in 2018 and is anticipated to maintain its dominance during the forecast period. This is attributed to increase in incidence of migraine, back pain, cancer pain, and others, which in turn fuels the adoption of opioids drugs.
North America accounted for the majority global opioid market share in 2018 and is anticipated to continue this trend during the forecast period. This is attributed to vigorous use and ease of availability of opioid analgesics in this region. However, Asia-Pacific is anticipated to grow at the fastest rate during the forecast period, owing to the presence of key players such as Teva Pharmaceuticals, Janssen Pharmaceuticals, Inc., and others in the region. Although opioids are vigorously used for pain management, the market is experiencing slow growth, owing to increase in cases of opioid crisis and deaths due to opioid overdose/misuse.
Key Benefits for Opioids Market:
This report entails a detailed quantitative analysis along with the current opioids market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
The market forecast is studied from 2018 to 2026.
The opioids market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
Comprehensive competitive analysis and profiles of major market players such as Purdue Pharma, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Sanofi, Sun Pharmaceuticals, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Allergan, Plc, Pfizer, Inc. have been provided in this report.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.